Personalized Medicine beyond Low-Density Lipoprotein Cholesterol to Combat Residual Risk for Coronary Artery Disease

Hayato Tada

Department of Cardiovascular Medicine, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan

Key words: LDL cholesterol, sd LDL cholesterol, Lipoprotein, Residual risk, Coronary artery disease

Assessing Residual Risks for Coronary Artery Disease

There are many biomarkers that have been shown as residual risks for coronary artery disease (CAD). Among them, serum lipids, including triglycerides (triglyceride-rich lipoproteins), lipoprotein (a) [Lp(a)], and small dense low-density lipoprotein (LDL) cholesterol (sd-LDL-C) can be considered as “established” residual risks, as not only observational studies but also post-hoc analysis of randomized controlled trial using statins, as well as Mendelian randomization studies suggested that these lipids appear to be associated with CAD, independent of LDL-C1-5. We need to keep in mind the simple fact that cholesterol is one of the major causes of atherosclerosis. In this sense, it is not surprising that these lipids containing cholesterol that are not cleared sufficiently from blood using statins are one of the major residual risks. Additionally, it is of note that there is some difference among these lipids regarding the effects on atherosclerosis. For example, triglyceride-rich lipoproteins is associated with myocardial infarction and peripheral artery disease, whereas, sd-LDL-C is associated with MI alone6). In this issue, Sekimoto et al. showed that the sd-LDL-C level was a residual risk for CAD in this statin era among patients with acute coronary syndrome7). The assessment of sd-LDL-C appears to be useful for the risk stratification beyond LDL-C because the total volume of LDL-C may not be reflecting accurate cardiovascular risk (Fig. 1). This information can be used as personalized medicine, at least for the risk prediction of various types of atherosclerotic disease.

Apolipoprotein B, “B” for Bad

Recent Mendelian randomization studies have suggested the causal relationships between these lipids and CAD. Although triglyceride-rich lipoproteins, Lp(a), and sd-LDL-C are all considered as lipids, we usually regard them as different properties. However, Ference et al. have shown that Mendelian randomization studies for LDL-C and triglycerides can be combined in one axis when we focus on apolipoprotein B, rather than triglycerides or LDL-C8). Regardless of the difference of the content, apolipoprotein B-containing lipoproteins are atherogenic, suggesting that “B” of apolipoprotein B stands for “bad” for atherosclerosis. In fact, we have shown that individuals with a protein-truncating mutation in APOB whose apolipoprotein B level is quite low exhibit extremely cardio-protective phenotype9).

Do not be Satisfied with the Assessments of LDL-C Alone

In our clinic, we typically assess LDL-C using the Friedwald’s formula. However, it has been shown that there are substantial differences regarding atherogenic properties among different sizes/densities of lipoproteins, even among “LDL” particles. We cannot differentiate clearly the atherogenic properties of LDL particles through the standard measurements of LDL-C. The assessments of sd-LCL-C should be considered, especially in the patients with metabolic syndrome, insulin resistance, and those who eat high-carbohydrate diet where the associations with...
sd-LDL-C are observed\(^\text{10}\). 

**Toward Personalized Medicine to Combat Residual Risks**

Based on the notion that sd-LDL-C appears to be causally associated with CAD, it can be used as an useful tool for personalized medicine, especially to combat the residual risk. Now, there are many agents to lower apolipoprotein B-containing lipoproteins on top of statins, including ezetimibe, resins, fibrates, proprotein convertase subtilisin/kexin type 9 inhibitors, polyunsaturated fatty acids, microsomal triglyceride transfer protein inhibitors, and bempedoic acids. Several more agents such as angiopoietin-like 3 inhibitor, antisense oligonucleotide for Lp(a), and apolipoprotein C3 inhibitor will be coming soon. We need more detailed data as to which agents are better for whom and for what reasons, including the effects on sd-LDL-C, and triglyceride-rich lipoproteins. This information should collectively lead to our more advanced personalized medicine to combat residual risk for CAD.

**Conclusion**

Apolipoprotein B-containing lipoproteins, including sd-LDL-C, are one of the established residual risk factors for CAD. We need to be much more careful for this variable, especially in the patients with metabolic syndrome, insulin resistance, and those who eat a high-carbohydrate diet.

---

**Acknowledgements**

None.

**Conflict of Interest**

None.

**Sources of Funding**

None.

**References:**

1) Tada H, Kawashiri MA, Nomura A, Yoshimura K, Itoh H, Komuro I, Yamagishi M. Serum triglycerides predict first cardiovascular events in diabetic patients with hypercholesterolemia and retinopathy. Eur J Prev Cardiol, 2018; 25: 1852-1860
2) Tada H, Kawashiri MA. Genetic Variations, Triglycerides, and Atherosclerotic Disease. J Atheroscler Thromb, 2019; 26: 128-131
3) Liou L, Kaptoge S. Association of small, dense LDL-cholesterol concentration and lipoprotein particle characteristics with coronary heart disease: A systematic review and meta-analysis. PLoS One, 2020; 15: e0241993
4) Tada H, Takamura M, Kawashiri MA. Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease. J Atheroscler Thromb, 2019; 26: 128-131
5) Higashioka M, Sakata S, Honda T, Hata J, Yoshida D, Hirakawa Y, Shibata M, Goto K, Kitazono T, Osawa H, Ninomiya T. Small Dense Low-Density Lipoprotein Cholesterol and the Risk of Coronary Heart Disease in a Japanese Community. J Atheroscler Thromb, 2020; 27: 669-682
6) Duran EK, Aday AW, Cook NR, Buring JE, Ridker PM, Pradhan AD. Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident Cardiovascular Disease. J Am Coll Cardiol, 2020; 75: 2122-2135

7) Sekimoto T, Koba S, Mori H, Sakai R, Arai T, Yokota Y, Sato S, Tanaka H, Masaki R, Oishi Y, Ogura K, Arai K, Nomura K, Kosaki R, Sakai K, Tsujita H, Kondo S, Tsukamoto S, Tsunoda F, Shoji M, Matsumoto H, Hamazaki Y, Shinke T. Small Dense Low-Density Lipoprotein Cholesterol: A Residual Risk for Rapid Progression of Non-Culprit Coronary Lesion in Patients with Acute Coronary Syndrome. J Atheroscler Thromb, 2021 in press. DOI: http://doi.org/10.5551/jat.60152

8) Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, Packard CJ, Laufs U, Oliver-Williams C, Wood AM, Butterworth AS, Di Angelantonio E, Danesh J, Nicholls SJ, Bhatt DL, Sabatine MS, Catapano AL. Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease. JAMA, 2019; 321: 364-373

9) Peloso GM, Nomura A, Khera AV, Chaffin M, Won HH, Ardissino D, Danesh J, Schunkert H, Wilson JG, Samani N, Erdmann J, McPherson R, Watkins H, Saleheen D, McCarthy S, Teslovich TM, Leader JB, Lester Kirchner H, Marrugat J, Nohara A, Kawashiri MA, Tada H, Dewey FE, Carey DJ, Baras A, Kathiresan S. Rare Protein-Truncating Variants in APOB, Lower Low-Density Lipoprotein Cholesterol, and Protection Against Coronary Heart Disease. Circ Genom Precis Med, 2019; 12: e002376

10) Fan J, Liu Y, Yin S, Chen N, Bai X, Ke Q, Shen J, Xia M. Small dense LDL cholesterol is associated with metabolic syndrome traits independently of obesity and inflammation. Nutr Metab (Lond), 2019; 16: 7